AW
ASBP

Avion Wealth’s Aspire Biopharma ASBP Stock Holding History

Avion Wealth’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Hold
45
– – ﹤0.01% 1188
2025
Q4 		$7K Hold
45
– – ﹤0.01% 602
2025
Q3 		$11K Buy
+45
New +$22.5K ﹤0.01% 465

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Avion Wealth's ASBP Position: Q1 2026 in Review

Avion Wealth held its Aspire Biopharma (ASBP) position steady in Q1 2026 at 45 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1188.

Avion Wealth first reported a position in ASBP in Q3 2025 and has held it in 3 quarters since. The position peaked at $11K in Q3 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Avion Wealth held 45 shares of Aspire Biopharma worth $1K as of Q1 2026.
  • Avion Wealth left its Aspire Biopharma share count unchanged in Q1 2026.
  • Aspire Biopharma made up ﹤0.01% of Avion Wealth's portfolio in Q1 2026, its #1188 holding.
  • Avion Wealth first reported a position in Aspire Biopharma in Q3 2025 and has held it in 3 quarters since.
  • Avion Wealth's Aspire Biopharma position peaked at $11K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Avion Wealth's 13F filing for Q1 2026, filed 1 May 2026.